Evidence map›Paper›PMID 28423529›Full record

ArticleOncotarget2017

PIF* promotes brain re-myelination locally while regulating systemic inflammation- clinically relevant multiple sclerosis M.smegmatis model.

Giuseppe Migliara, Martin Mueller, Alessia Piermattei, Chaya Brodie, Michael J Paidas, Eytan R Barnea, Francesco Ria

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Giuseppe MigliaraUniversità Cattolica del S. Cuore, Institute of General Pathology, Largo Francesco Vito, 100168 Rome, Italy.
Martin MuellerDepartment of Obstetrics and Gynecology, University of Bern, 3010, Bern, Switzerland.
Alessia PiermatteiUniversità Cattolica del S. Cuore, Institute of General Pathology, Largo Francesco Vito, 100168 Rome, Italy.
Chaya BrodieDepartment of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA.
Michael J PaidasDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, Yale University School of Medicine, FMB 3398, New Haven, CT 06520-8063, USA.
Eytan R BarneaSociety for the Investigation of Early Pregnancy (SIEP), Cherry Hill, NJ 08003, USA.
Francesco RiaUniversità Cattolica del S. Cuore, Institute of General Pathology, Largo Francesco Vito, 100168 Rome, Italy.
Università Cattolica del Sacro Cuore · ITChildren's Center · USHenry Ford Hospital · USSociety for the Investigation of Early Pregnancy · USUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurologic disease diagnosis and treatment is challenging. Multiple Sclerosis (MS) is a demyelinating autoimmune disease with few clinical forms and uncertain etiology. Current studies suggest that it is likely caused by infection(s) triggering a systemic immune response resulting in antigen/non-antigen-related autoimmune response in central nervous system (CNS). New therapeutic approaches are needed. Secreted by viable embryos, PreImplantation Factor (PIF) possesses a local and systemic immunity regulatory role. Synthetic PIF (PIF) duplicates endogenous peptide's protective effect in pre-clinical autoimmune and transplantation models. PIF protects against brain hypoxia-ischemia by directly targeting microglia and neurons. In chronic experimental autoimmune encephalitis (EAE) model PIF reverses paralysis while promoting neural repair. Herein we report that PIF directly promotes brain re-myelination and reverses paralysis in relapsing remitting EAE MS model. PIF crosses the blood-brain barrier targeting microglia. Systemically, PIF decreases pro-inflammatory IL23/IL17 cytokines, while preserving CNS-specific T-cell repertoire. Global brain gene analysis revealed that PIF regulates critical Na+/K+/Ca++ ions, amino acid and glucose transport genes expression. Further, PIF modulates oxidative stress, DNA methylation, cell cycle regulation, and protein ubiquitination while regulating multiple genes. In cultured astrocytes, PIF promotes BDNF-myelin synthesis promoter and SLC2A1 (glucose transport) while reducing deleterious E2F5, and HSP90ab1 (oxidative stress) genes expression. In cultured microglia, PIF increases anti-inflammatory IL10 while reducing pro-inflammatory IFNγ expression. Collectively, PIF promotes brain re-myelination and neuroprotection in relapsing remitting EAE MS model. Coupled with ongoing, Fast-Track FDA approved clinical trial, NCT#02239562 (immune disorder), current data supports PIF's translation for neurodegenerative disorders therapy.

Indexed as

AnimalsBrainEncephalomyelitis, Autoimmune, ExperimentalFemaleGene Expression ProfilingInflammationMiceMultiple Sclerosis, Relapsing-RemittingMycobacterium Infections, NontuberculousMycobacterium smegmatisMyelin SheathPeptidesReal-Time Polymerase Chain ReactionTranscriptomePeptidespreimplantation factor, syntheticM. smegmatis bacterianeuroprotectionneuroregenerationpreImplantation factorRR-EAE clinically-relevant model

Identifiers

PMID28423529
PMCPMC5400627
OpenAlexW2590262026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.